andexanet alfa

Brand: Andexxa

Prototype Drug
Drug Class: anticoagulant reversal agent
Drug Family: reversal agent
Subclass: recombinant modified factor Xa (decoy)
Organ Systems: cardiovascularhematology-oncology

Mechanism of Action

Recombinant modified factor Xa lacking catalytic activity acting as decoy receptor; competitively binds and sequesters direct Xa inhibitors (rivaroxaban, apixaban); also reverses LMWH/fondaparinux partially.

factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)

Indications

  • reversal of rivaroxaban or apixaban for life-threatening bleeding

Contraindications

  • no absolute contraindications; not approved for dabigatran reversal

Adverse Effects

Common

  • hypersensitivity reactions

Serious

  • thromboembolic events (rebound prothrombotic state)
  • arteriolar thrombosis

Pharmacokinetics (ADME)

Absorption IV only
Distribution intravascular
Metabolism proteolytic degradation
Excretion proteolysis
Half-life ~1 hour
Onset immediate IV
Peak immediate
Duration 2-4 hours
Protein Binding <0%
Vd low

Drug Interactions

Drug / Agent Mechanism Severity
rivaroxaban/apixaban specific reversal — beneficial beneficial

Nursing Considerations

  1. ANNEXA-4 study: effective reversal of anti-Xa activity within 2-5 minutes
  2. Two dosing regimens based on which drug and when last dose taken
  3. Thrombosis risk: anti-Xa reversal may lead to rebound pro-thrombotic state; restart anticoagulation as soon as clinically safe
  4. Very expensive (>$25,000 per dose); 4-factor PCC is an alternative

Clinical Pearls

  • Decoy mechanism: acts as competitive 'trap' for Xa inhibitors; does not carry catalytic activity so does not cause thrombosis directly
  • ANNEXA-4: hemostatic efficacy in 82% for apixaban, 79% for rivaroxaban — 30-day thrombosis rate elevated vs historical

Safety Profile

Pregnancy insufficient-data
Lactation insufficient-data
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Guideline Update pending

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.